FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.

7-hydroxycoumarinyl-γ-Linolenate is a γ-linolenic acid ester of 7-hydroxycoumarin (umbelliferone) that behaves as a substrate for cPLA2. Hydrolysis of 7-hydroxycoumarinyl-γ-linolenate by phospholipase results in the release of the fluorescent compound 7-hydroxycoumarin which can be monitored spectrophotometrically (excitation at 335 nm, emission at 450 nm).

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.